Skip to main content

Multiple Sclerosis Topic Center

A doctor looks at a brain scan
News
11/04/2025
Brionna Mendoza
In the Phase 2 MoonStone trial of obexelimab in relapsing multiple sclerosis (rMS), the investigational drug met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhacing (GdE) T1 hyperintense lesions over week 8 and...
In the Phase 2 MoonStone trial of obexelimab in relapsing multiple sclerosis (rMS), the investigational drug met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhacing (GdE) T1 hyperintense lesions over week 8 and...
In the Phase 2 MoonStone trial...
11/04/2025
Neurology
an older woman sits on a couch looking out the window
News
10/10/2025
Brionna Mendoza
Menopause was not found to drive disease progression in multiple sclerosis (MS) in women at midlife. Results from the longitudinal cohort study were published in JAMA Neurology.
Menopause was not found to drive disease progression in multiple sclerosis (MS) in women at midlife. Results from the longitudinal cohort study were published in JAMA Neurology.
Menopause was not found to drive...
10/10/2025
Neurology
a head in profile with a heart over where the brain would be against a teal background
News
07/30/2025
Brionna Mendoza
Multiple sclerosis (MS) may increase the risk of developing Alzheimer disease (AD), according to an analysis of genetic data published in Neurodegenerative Disease Management.
Multiple sclerosis (MS) may increase the risk of developing Alzheimer disease (AD), according to an analysis of genetic data published in Neurodegenerative Disease Management.
Multiple sclerosis (MS) may...
07/30/2025
Neurology
A teddy bear against a blue background wearing a mask and stethoscope.
News
06/11/2025
Brionna Mendoza
A new study suggests that biological aging may be accelerated in children living with multiple sclerosis (MS).
A new study suggests that biological aging may be accelerated in children living with multiple sclerosis (MS).
A new study suggests that...
06/11/2025
Neurology
illustration of the brain in white lines against a black background
News
06/09/2025
Jolynn Tumolo
Researchers have identified a combination of factors that confers a 58.3% risk of the development of multiple sclerosis (MS) over 5 years in people with radiologically isolated syndrome (pwRIS).
Researchers have identified a combination of factors that confers a 58.3% risk of the development of multiple sclerosis (MS) over 5 years in people with radiologically isolated syndrome (pwRIS).
Researchers have identified a...
06/09/2025
Neurology
a human hand holds a Vitamin D supplement pill against a background of clouds in the sky on a sunny day
News
03/20/2025
Jolynn Tumolo
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced disease activity over 24 months in patients with clinically isolated syndrome typical for multiple sclerosis (MS) and early relapsing-remitting MS, according to study results published in JAMA.
High-dose vitamin D reduced...
03/20/2025
Neurology
News
02/10/2025
Lisa Kuhns, PhD, MD
Individuals with multiple sclerosis (MS) experience an ongoing impact of post-COVID-19 symptoms, revealing a significant overlap between post-acute sequelae of SARS-CoV-2 infection (PASC) and MS-related symptoms.
Individuals with multiple sclerosis (MS) experience an ongoing impact of post-COVID-19 symptoms, revealing a significant overlap between post-acute sequelae of SARS-CoV-2 infection (PASC) and MS-related symptoms.
Individuals with multiple...
02/10/2025
First Report Managed Care
Injectable Medication
News
02/06/2025
Jolynn Tumolo
The U.S. FDA is warning of rare, life-threatening allergic reactions associated with the injectable MS drug glatiramer acetate. Since its approval in 1996, 82 patients worldwide have required emergency care or hospitalization for anaphylaxis...
The U.S. FDA is warning of rare, life-threatening allergic reactions associated with the injectable MS drug glatiramer acetate. Since its approval in 1996, 82 patients worldwide have required emergency care or hospitalization for anaphylaxis...
The U.S. FDA is warning of rare,...
02/06/2025
Neurology
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
11/01/2024
Jolynn Tumolo
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
10/15/2024
Jolynn Tumolo
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology